BERKELEY, Calif., April 20 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) will announce its first quarter 2006 financial results on Thursday, April 27, 2006.
The announcement will be followed by a live webcast at 5:00 p.m. ET of a discussion by Dynavax Technologies management of first quarter 2006 financial results.
The webcast can be accessed on Dynavax Technologies' website at http://www.dynavax.com . The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.fulldisclosure.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com).
An audio replay of the webcast will be available until May 4, 2006 by dialing 888-286-8010; conference identification number 62341632. International callers can dial 617-801-6888; conference identification number 62341632.
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax's pipeline includes: TOLAMBA™, a ragweed allergy immunotherapeutic, that has completed a large-scale Phase 2/3 clinical trial, and is in a supportive clinical trial in ragweed allergic children; HEPLISAV™, a hepatitis B vaccine that is currently in a pivotal Phase 3 clinical trial; SUPERVAX, a two-dose hepatitis B vaccine; an asthma immunotherapeutic that has shown preliminary safety and pharmacologic activity in a Phase 2a clinical trial; a cancer therapy currently in a Phase 2 clinical trial for non-Hodgkins lymphoma and in preclinical development in solid tumors; and preclinical programs in hepatitis B and hepatitis C therapy.
SOURCE Dynavax Technologies
CONTACT: Jane M. Green, PhD, Vice President, Corporate Communications of Dynavax Technologies Corporation, +1-510-665-4630, or firstname.lastname@example.org
Web site: http://www.dynavax.com
04/20/2006 16:00 EDT http://www.prnewswire.com